A BILL 
To amend title XVIII of the Social Security Act to encourage 
the development and use of DISARM antimicrobial 
drugs, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Developing an Innova-
4
tive Strategy for Antimicrobial Resistant Microorganisms 
5
Act of 2019’’ and as the ‘‘DISARM Act of 2019’’. 
6
00:14 Aug 15, 2019
H4100
2 
•HR 4100 IH
SEC. 2. ENCOURAGING THE DEVELOPMENT AND USE OF 
1
DISARM ANTIMICROBIAL DRUGS. 
2
(a) ADDITIONAL PAYMENT
FOR DISARM ANTI-
3
MICROBIAL DRUGS UNDER MEDICARE.— 
4
(1) IN GENERAL.—Section 1886(d)(5) of the 
5
Social Security Act (42 U.S.C. 1395ww(d)(5)) is 
6
amended by adding at the end the following new 
7
subparagraph: 
8
‘‘(M)(i)(I) Effective for discharges beginning on or 
9
after October 1, 2020, or such sooner date as specified 
10
by the Secretary, subject to subclause (II), the Secretary 
11
shall, after notice and opportunity for public comment (in 
12
the publications required by subsection (e)(5) for a fiscal 
13
year or otherwise), provide for an additional payment 
14
under a mechanism (separate from the mechanism estab-
15
lished under subparagraph (K)), with respect to such dis-
16
charges involving any DISARM antimicrobial drug, in an 
17
amount equal to— 
18
‘‘(aa) the amount payable under section 1847A 
19
for such drug during the calendar quarter in which 
20
the discharge occurred; or 
21
‘‘(bb) if no amount for such drug is determined 
22
under section 1847A, an amount to be determined 
23
by the Secretary in a manner similar to the manner 
24
in which payment amounts are determined under 
25
section 1847A based on information submitted by 
26
00:14 Aug 15, 2019
H4100
3 
•HR 4100 IH
the manufacturer or sponsor of such drug (as re-
1
quired under clause (v)). 
2
‘‘(II) In determining the amount payable under sec-
3
tion 1847A for purposes of items (aa) and (bb) of sub-
4
clause (I), subparagraphs (A) and (B) of subsection (b)(1) 
5
of such section shall be applied by substituting ‘102 per-
6
cent’ for ‘106 percent’ each place it appears and para-
7
graph (8)(B) of such section shall be applied by sub-
8
stituting ‘2 percent’ for ‘6 percent’. 
9
‘‘(ii) For purposes of this subparagraph, a DISARM 
10
antimicrobial drug is— 
11
‘‘(I) a drug— 
12
‘‘(aa) that— 
13
‘‘(AA) is approved by the Food and 
14
Drug Administration; 
15
‘‘(BB) is designated by the Food and 
16
Drug Administration as a qualified infec-
17
tious disease product under subsection (d) 
18
of section 505E of the Federal Food, 
19
Drug, and Cosmetic Act; and 
20
‘‘(CC) has received an extension of its 
21
exclusivity period pursuant to subsection 
22
(a) of such section; and 
23
00:14 Aug 15, 2019
H4100
4 
•HR 4100 IH
‘‘(bb) that has been designated by the Sec-
1
retary pursuant to the process established 
2
under clause (iv)(I)(bb); or 
3
‘‘(II) an antibacterial or antifungal biological 
4
product— 
5
‘‘(aa) that is licensed for use, or an anti-
6
bacterial or antifungal biological product for 
7
which an indication is first licensed for use, by 
8
the Food and Drug Administration on or after 
9
June 5, 2014, under section 351(a) of the Pub-
10
lic Health Service Act for human use to treat 
11
serious or life-threatening infections, as deter-
12
mined by the Food and Drug Administration, 
13
including those caused by, or likely to be caused 
14
by— 
15
‘‘(AA) an antibacterial or antifungal 
16
resistant pathogen, including novel or 
17
emerging infectious pathogens; or 
18
‘‘(BB) a qualifying pathogen (as de-
19
fined under section 505E(f) of the Federal 
20
Food, Drug, and Cosmetic Act); and 
21
‘‘(bb) has been designated by the Secretary 
22
pursuant to the process established under 
23
clause (iv)(I)(bb). 
24
00:14 Aug 15, 2019
H4100
5 
•HR 4100 IH
‘‘(iii) The mechanism established pursuant to clause 
1
(i) shall provide that the additional payment under clause 
2
(i) shall— 
3
‘‘(I) with respect to a discharge, only be made 
4
to a subsection (d) hospital that, as determined by 
5
the Secretary— 
6
‘‘(aa) is participating in the National 
7
Healthcare Safety Network Antimicrobial Use 
8
and Resistance Module of the Centers for Dis-
9
ease Control and Prevention; and 
10
‘‘(bb) has an antimicrobial stewardship 
11
program that aligns with the Core Elements of 
12
Hospital Antibiotic Stewardship Programs of 
13
the Centers for Disease Control and Prevention 
14
or the Antimicrobial Stewardship Standard set 
15
by the Joint Commission; and 
16
‘‘(II) apply to discharges occurring on or after 
17
October 1 of the year in which the drug or biological 
18
product is designated by the Secretary as a DIS-
19
ARM antimicrobial drug. 
20
For purposes of this clause, in the case of a similar report-
21
ing program described in item (aa), a subsection (d) hos-
22
pital shall be treated as participating in such a program 
23
if the entity maintaining such program identifies to the 
24
Secretary such hospital as so participating. 
25
00:14 Aug 15, 2019
H4100
6 
•HR 4100 IH
‘‘(iv)(I) The mechanism established pursuant to 
1
clause (i) shall provide for a process for— 
2
‘‘(aa) a manufacturer or sponsor of a drug or 
3
biological product to request the Secretary to des-
4
ignate the drug or biological product as a DISARM 
5
antimicrobial drug; and 
6
‘‘(bb) the designation (and removal of such des-
7
ignation) by the Secretary of drugs and biological 
8
products as DISARM antimicrobial drugs. 
9
‘‘(II) A designation of a drug or biological product 
10
as a DISARM antimicrobial drug may be revoked by the 
11
Secretary if the Secretary determines that— 
12
‘‘(aa) the drug or biological product no longer 
13
meets the requirements for a DISARM antimicrobial 
14
drug under clause (ii); 
15
‘‘(bb) the request for such designation con-
16
tained an untrue statement of material fact; or 
17
‘‘(cc) clinical or other information that was not 
18
available to the Secretary at the time such designa-
19
tion was made shows that— 
20
‘‘(AA) such drug or biological product is 
21
unsafe for use or not shown to be safe for use 
22
for individuals who are entitled to benefits 
23
under part A; or 
24
00:14 Aug 15, 2019
H4100
7 
•HR 4100 IH
‘‘(BB) an alternative to such drug or bio-
1
logical product is an advance that substantially 
2
improves the diagnosis or treatment of such in-
3
dividuals. 
4
‘‘(III) Not later than October 1, 2020, the Secretary 
5
shall publish in the Federal Register a list of the DISARM 
6
antimicrobial drugs designated under this subparagraph 
7
pursuant to the process established under subclause 
8
(I)(bb). The Secretary shall annually update such list. 
9
‘‘(v)(I) For purposes of determining additional pay-
10
ment amounts under clause (i), a manufacturer or sponsor 
11
of a drug or biological product that submits a request de-
12
scribed in clause (iv)(I)(aa) shall submit to the Secretary 
13
information described in section 1927(b)(3)(A)(iii). 
14
‘‘(II) The penalties for failure to provide timely infor-
15
mation under clause (i) of subparagraph (C) section 
16
1927(b)(3) and for providing false information under 
17
clause (ii) of such subparagraph shall apply to manufac-
18
turers and sponsors of a drug or biological product under 
19
this section with respect to information under subclause 
20
(I) in the same manner as such penalties apply to manu-
21
facturers under such clauses with respect to information 
22
under subparagraph (A) of such section. 
23
‘‘(vi)(I) The mechanism established pursuant to 
24
clause (i) shall provide that— 
25
00:14 Aug 15, 2019
H4100
8 
•HR 4100 IH
‘‘(aa) except as provided in item (bb), no addi-
1
tional payment shall be made under this subpara-
2
graph for discharges involving a DISARM anti-
3
microbial drug if any additional payments have been 
4
made for discharges involving such drug as a new 
5
medical service or technology under subparagraph 
6
(K); 
7
‘‘(bb) additional payments may be made under 
8
this subparagraph for discharges involving a DIS-
9
ARM antimicrobial drug if any additional payments 
10
have been made for discharges occurring prior to the 
11
date of enactment of this subparagraph involving 
12
such drug as a new medical service or technology 
13
under subparagraph (K); and 
14
‘‘(cc) no additional payment shall be made 
15
under subparagraph (K) for discharges involving a 
16
DISARM antimicrobial drug as a new medical serv-
17
ice or technology if any additional payments for dis-
18
charges involving such drug have been made under 
19
this subparagraph.’’. 
20
(2) 
CONFORMING
AMENDMENT.—Section 
21
1886(d)(5)(K)(ii)(III) of the Social Security Act (42 
22
U.S.C. 1395ww(d)(5)(K)(ii)(III)) is amended by 
23
striking ‘‘provide’’ and inserting ‘‘subject to sub-
24
paragraph (M)(vii), provide’’. 
25
00:14 Aug 15, 2019
H4100
9 
•HR 4100 IH
(b) STUDY AND REPORTS ON REMOVING BARRIERS 
1
TO
THE DEVELOPMENT
OF DISARM ANTIMICROBIAL 
2
DRUGS.— 
3
(1) STUDY.—The Comptroller General of the 
4
United States (in this subsection referred to as the 
5
‘‘Comptroller General’’) shall, in consultation with 
6
the Director of the National Institutes of Health, 
7
the Commissioner of Food and Drugs, the Adminis-
8
trator of the Centers for Medicare & Medicaid Serv-
9
ices, and the Director of the Centers for Disease 
10
Control and Prevention, conduct a study to— 
11
(A) identify and examine the barriers that 
12
prevent the development of DISARM anti-
13
microbial 
drugs 
(as 
defined 
in 
section 
14
1886(d)(5)(M)(ii) of the Social Security Act, as 
15
added by subsection (a)); and 
16
(B) develop recommendations for actions 
17
to be taken in order to overcome any barriers 
18
identified under subparagraph (A). 
19
(2) REPORTS.— 
20
(A) INTERIM REPORT.—Not later than 3 
21
years after the date of the enactment of this 
22
Act, the Comptroller General shall submit to 
23
Congress an interim report containing the pre-
24
liminary results of the study conducted under 
25
00:14 Aug 15, 2019
H4100
10 
•HR 4100 IH
paragraph (1), together with recommendations 
1
for such legislation and administrative action as 
2
the Comptroller General determines appro-
3
priate. 
4
(B) FINAL
REPORT.—Not later than 5 
5
years after the date of the enactment of this 
6
Act, the Comptroller General shall submit to 
7
Congress a report containing the results of the 
8
study conducted under paragraph (1), together 
9
with recommendations for such legislation and 
10
administrative action as the Comptroller Gen-
11
eral determines appropriate. 
12
Æ 
00:14 Aug 15, 2019
H4100
